Robert Hoffman - Kintara Therapeutics Independent Director

Director

Mr. Robert E. Hoffman is Chairman of the Board of the Company. Mr. Hoffman has served as a member of Kura Oncology, Inc.s Board of Directors since March 2015. Mr. Hoffman has served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc., a publiclyheld pharmaceutical company since April 2017. Prior to joining Heron Therapeutics, Inc., Mr. Hoffman served as Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals, Inc., a publiclyheld pharmaceutical company, from September 2016 to April 2017. From July 2015 to September 2016, Mr. Hoffman served as Chief Financial Officer of AnaptysBio, Inc., a publiclyheld biotechnology company. From June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President, Finance and Chief Financial Officer of Arena Pharmaceuticals, Inc., or Arena, a publiclyheld biopharmaceutical company. From August 2011 to June 2012 and previously from December 2005 to March 2011, he served as Arenas Vice President, Finance and Chief Financial Officer and in a number of various roles of increasing responsibility from 1997 to December 2005. From March 2011 to August 2011, Mr. Hoffman served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company. Mr. Hoffman formerly served as a member of the Board of Directors of CombiMatrix Corporationrationration, a molecular diagnostics company, and MabVax Therapeutics Holdings, Inc., a biopharmaceutical company. Mr. Hoffman serves as a member of the Financial Accounting Standards Boards Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman formerly served as a director and President, of the San Diego Chapter of Financial Executives International since 2018.
Age 52
Tenure 6 years
Professional MarksCPA
Phone858-350-4364
Webhttp://www.delmarpharma.com
Hoffman holds a B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. in the State of California.

Kintara Therapeutics Management Efficiency

The company has return on total asset (ROA) of (136.86) % which means that it has lost $136.86 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (316.72) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics' management efficiency ratios could be used to measure how well Kintara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

DIRECTOR Age

Paul LeandSFL Corporation
50
Andrew NinerHurco Companies
40
Donald LuckyMYR Group
55
John BoxCentury Communities
74
William KacalUS Silica Holdings
72
Georgina SousaSFL Corporation
66
Donald YoungNewpark Resources
48
Harald ThorsteinSFL Corporation
38
James McFarlandNewpark Resources
68
Brian FeldottNewpark Resources
N/A
Bert BekkerSFL Corporation
80
Bradley FavreauMYR Group
34
Roderick LarsonNewpark Resources
53
Rose RobesonNewpark Resources
60
Thomas AaroHurco Companies
60
Kate BlankenshipSFL Corporation
52
Claudio CorninForsys Metals Corp
N/A
Michael LawsonUS Silica Holdings
N/A
Paul MatysekForsys Metals Corp
N/A
James LippmanCentury Communities
63
Jennifer LowryMYR Group
49
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California. DelMar Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people. Kintara Therapeutics (DMPI) is traded on NASDAQ Exchange in USA and employs 2 people.

Management Performance

Kintara Therapeutics Leadership Team

Elected by the shareholders, the Kintara Therapeutics' board of directors comprises two types of representatives: Kintara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kintara. The board's role is to monitor Kintara Therapeutics' management team and ensure that shareholders' interests are well served. Kintara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kintara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Scott Praill, CFO and Principal Accounting Officer
John Bell, Independent Director
William Garner, Director
Erich Mohr, Independent Director
Saiid Zarrabian, Director
Robert Toth, Director
Dennis Brown, Chief Scientific Officer, Director
Jeffrey Bacha, President CEO, Director
Lynda Cranston, Independent Director
Robert Hoffman, Independent Director
Napoleone Ferrara, Director

Kintara Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kintara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kintara Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kintara Therapeutics' short interest history, or implied volatility extrapolated from Kintara Therapeutics options trading.

Pair Trading with Kintara Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kintara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kintara Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Tenet Healthcare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tenet Healthcare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tenet Healthcare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tenet Healthcare to buy it.
The correlation of Tenet Healthcare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tenet Healthcare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tenet Healthcare moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tenet Healthcare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Consideration for investing in Kintara Stock

If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings